RT Journal Article SR Electronic T1 Emergence of Resistance to Fluoroquinolones and Third-Generation Cephalosporins in Salmonella Typhi in Lahore, Pakistan JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.12.20020578 DO 10.1101/2020.02.12.20020578 A1 Farhan Rasheed A1 Muhammad Saeed A1 Nabil-Fareed Alikhan A1 David Baker A1 Mohsin Khurshid A1 Emma V. Ainsworth A1 A. Keith Turner A1 Ambereen Anwar Imran A1 Muhammad Hidayat Rasool A1 Muhammad Saqalein A1 Muhammad Atif Nisar A1 Muhammad Fayyaz Ur Rehman A1 John Wain A1 Muhammad Yasir A1 Gemma C. Langridge A1 Aamer Ikram YR 2020 UL http://medrxiv.org/content/early/2020/02/13/2020.02.12.20020578.abstract AB Background Extensively drug-resistant (XDR) Salmonella Typhi has been reported in Sindh province of Pakistan since 2016. The potential for further spread is of serious concern as remaining treatment options are severely limited. We report the phenotypic and genotypic characterisation of 27 XDR S. Typhi isolated from patients attending Jinnah Hospital, Lahore, Pakistan.Methods Isolates were identified by biochemical profiling; antimicrobial susceptibility was determined by a modified Kirby-Bauer method. These findings were confirmed using Illumina whole genome nucleotide sequence data. All sequences were compared to the outbreak strain from southern Pakistan and typed using the S. Typhi genotyping scheme.Findings Twenty-seven XDR S. Typhi isolates were identified from patients at Jinnah Hospital in Lahore between January and April 2019. All isolates were confirmed by sequence analysis to harbour an IncY plasmid and the CTX-M-15 ceftriaxone resistance determinant. All isolates were of the same genotypic background as the outbreak strain from Sindh province.Summary We report the first emergence of XDR S. Typhi in Punjab province of Pakistan confirmed by whole genome sequencing.Funding This work was supported by the BBSRC-funded QIB Institute Strategic Programme “Microbes in the Food Chain” BB/R012504/1 and its constituent projects Microbial Survival in the Food Chain (BBS/E/F/000PR10349) and Research Infrastructure (BBS/E/F/000PR10352), and the BBSRC funded Core Capability Grant (project number BB/CCG1860/1).Evidence before this study Typhoid fever is endemic in Pakistan, with widespread resistance to first line drugs: ampicillin, co-trimoxazole, and chloramphenicol, and to fluoroquinolones. In 2017 the first report of additional resistance to ceftriaxone was published as XDR typhoid fever from southern Pakistan. Treatment of XDR typhoid fever has been a clinical challenge; options are scarce, and the level of chronic carriage is unknown. Current treatment is dependent upon azithromycin and this represents a major threat for the community as resistance has been reported from Bangladesh.Added value of this study This study is the first genomic report of XDR typhoid fever in a central part of Pakistan, describing the same genetic background as strains responsible for XDR typhoid in Sindh province. We have confirmed that the outbreak strain of XDR S. Typhi is now present in the most populated province and second largest city of Pakistan.Implications of all the available evidence The present study highlights the gravity of the situation - the spread of this strain is of serious concern. The clinical situation remains unchanged since this study was performed; we believe it is imperative that future research focuses upon the biology, transmission and control of this strain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the BBSRC-funded QIB Institute Strategic Programme “Microbes in the Food Chain” BB/R012504/1 and its constituent projects Microbial Survival in the Food Chain (BBS/E/F/000PR10349) and Research Infrastructure (BBS/E/F/000PR10352), and the BBSRC funded Core Capability Grant (project number BB/CCG1860/1).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary Material available Table S1. Anonymised patient data Table S2. Antimicrobial susceptibility testing results